Amicus Therapeutics and the Perelman School of Medicine at the University of Pennsylvania have announced a major expansion to their R&D collaboration for gene therapies.
A bumper crop of orphan drugs from the likes of Amicus, Kyowa Kirin, Eusa and Biogen dominates this year’s UK Prix Galien shortlist as biotech firms and specialist pharma companies cement t
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh